Discover
UPB
Upstream Bio, Inc.
7.28
2 x 5.33
2 x 8.83
bid
ask
+
0.36
5.20%
2 @ 04:00 PM
7.33 +0.05 (0.69%)
| Ytd | -73.19% | |
| 1y | -34.59% |
6.81
day range
7.42
5.85
52 week range
33.68
| Open | 6.90 | Prev Close | 6.92 | Low | 6.81 | High | 7.42 | Mkt Cap | 396.18M |
| Vol | 548.44K | Avg Vol | 606.57K | EPS | -2.90 | P/E | N/A | Forward P/E | -2.45 |
| Beta | N/A | Short Ratio | 2.45 | Inst. Own | 94.73% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 7.95 | 200-d Avg | 17.10 | 1yr Est | 47.86 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-03-11 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | 0.15 | 19.23% |
| 2025-08-06 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-06 | 2025-06 | 0 | N/A | -0.13 | -21.31% |
| 2025-05-06 | 2025-03 | 0 | N/A | -0.02 | -4.08% |
| 2025-05-06 | 2025-03 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-27 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2025-12-18 | Mizuho | Upgrade | Outperform | |
| 2025-12-02 | LifeSci Capital | Upgrade | Outperform | |
| 2025-11-18 | Evercore ISI Group | Upgrade | Outperform | |
| 2025-10-14 | Truist Securities | Upgrade | Buy | |
| 2024-11-05 | JP Morgan | Upgrade | Overweight |
Profile
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-14 | AI UPSTREAM LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-03-15 | AMBROSE ALLISON | General Counsel | 16.52K | Sale |
| 2024-10-14 | CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-03-15 | DEYKIN AARON M.D. | Officer | 32.69K | Sale |
| 2026-03-15 | GRAY MICHAEL P | Chief Operating Officer | 29.65K | Sale |
| 2026-03-15 | HOUGHTON ADAM | Officer | 24.30K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | FMR, LLC | 7.52M | 65.18M | 13.91% |
| 2025-12-30 | Orbimed Advisors LLC. | 5.69M | 49.36M | 10.54% |
| 2025-12-30 | Blackrock Inc. | 3.34M | 29.00M | 6.19% |
| 2025-12-30 | Decheng Capital LLC | 3.14M | 27.25M | 5.82% |
| 2025-12-30 | NORGES BANK | 2.88M | 24.99M | 5.33% |
| 2025-12-30 | Enavate Sciences Gp, LLC | 2.46M | 21.33M | 4.55% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.44M | 12.51M | 2.67% |
| 2025-12-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.37M | 11.89M | 2.54% |
| 2026-01-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 800.00K | 6.94M | 1.48% |
| 2026-01-30 | iShares Trust-iShares Russell 2000 ETF | 780.26K | 6.76M | 1.44% |
| 2026-01-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 691.00K | 5.99M | 1.28% |
| 2025-12-30 | Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 682.02K | 5.91M | 1.26% |